Mr Peter Sands, Executive Director, The Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria

Mr Sands, we first learned about precision medicine and now there’s something called precision prevention in public health. Can you explain a little more how this works and why it makes investment sense?

We first learned about precision medicine and now there’s something called precision prevention in public health. Can you explain a little more how this works and why it makes investment sense?

1. We know that the gaps in services for HIV prevention remain large. And although we are increasing GF resources and attention to prevention, along with other donors and some governments, the financing gap is also large – and under greater threat with Covid and its economic consequences.

2. These gaps mean we need to focus. We are advancing the concept of Precision Prevention to ensure that we get maximum impact from the scarce resources that are available, that we get the best outcomes, the best value for money, for our investments. This requires a collective effort.

3. Precision Prevention means ensuring that the people with the greatest HIV prevention needs — have the tools, knowledge and power to protect themselves from acquiring HIV. We are signaling an effort to move away from generalized and untargeted investments towards high impact interventions for people who need them most, in locations where HIV is most prevalent. We are investing in data systems, and community delivery platforms so that communities themselves have the knowledge, power and capacity to make good decisions about what to prioritise in HIV prevention programs. We are emphasizing improved condom programming, PrEP scale up and VMMC and we want to ensure that new prevention products such as HIV self tests, the new vaginal ring, and new formulations for PrEP (such as injectable, long acting PrEP) are key to our prevention investments, and the results that we anticipate. We are also emphasizing greater scale - especially for key population prevention programs - and greater prioritization of HIV prevention investments for AGYW.

4. ‘Precision’ public health’ is not unique to the Global Fund – it is a means of improving population health using new technologies, and data to guide public health investment and practice by generating tailored interventions and policies and better targeted responses. Using precise data to target disease prevention and control, and to improve health and health equity - with a focus on reducing health inequalities.
5. Along with this focus on the right tools in the hands of the people who need them most, we will continue to emphasize critical and supportive efforts to reform policies and practices (health care worker practices, policing practices) to address barriers to HIV prevention. We will continue to invest to support communities most at risk of HIV to be at the table when prevention programs are planned and delivered.

6. We support 100 + countries with financing for medicines and health products, procured by the Global Fund at approximately $2Bn per annum. Procurement and supply management of health products are fundamental to the performance of Global Fund-supported programs.